GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease

Heng Chih Pan; Jui Yi Chen; Hsing Yu Chen; Fang Yu Yeh; Chiao Yin Sun; Thomas Tao Min Huang; Vin Cent Wu

doi:10.1038/s41467-024-50199-y

GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease

Heng Chih Pan
, Jui Yi Chen
, Hsing Yu Chen
, Fang Yu Yeh
, Chiao Yin Sun
, Thomas Tao Min Huang
, Vin Cent Wu^*

^*Corresponding author for this work

School of Traditional Chinese Medicine

National Taiwan University
Chang Gung University
Chang Gung Memorial Hospital
Chi-Mei Medical Center
Chia Nan University of Pharmacy and Science

Research output: Contribution to journal › Journal Article › peer-review

73 Scopus citations

Abstract

Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.

Original language	English
Article number	5912
Pages (from-to)	5912
Journal	Nature Communications
Volume	15
Issue number	1
DOIs	https://doi.org/10.1038/s41467-024-50199-y
State	Published - 13 07 2024

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Humans
Diabetes Mellitus, Type 2/drug therapy
Glucagon-Like Peptide-1 Receptor/agonists
Male
Female
Middle Aged
Aged
Acute Kidney Injury/mortality
Hypoglycemic Agents/therapeutic use
Cardio-Renal Syndrome/drug therapy
Cardiovascular Diseases/mortality
Treatment Outcome
Glucagon-Like Peptide-1 Receptor Agonists

Access to Document

10.1038/s41467-024-50199-y

Cite this

@article{673e793f142744278bea3f184c6fd6d0,

title = "GLP-1 receptor agonists{\textquoteright} impact on cardio-renal outcomes and mortality in T2D with acute kidney disease",

abstract = "Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2\%) and cardiorenal syndrome (34.2\%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.",

keywords = "Humans, Diabetes Mellitus, Type 2/drug therapy, Glucagon-Like Peptide-1 Receptor/agonists, Male, Female, Middle Aged, Aged, Acute Kidney Injury/mortality, Hypoglycemic Agents/therapeutic use, Cardio-Renal Syndrome/drug therapy, Cardiovascular Diseases/mortality, Treatment Outcome, Glucagon-Like Peptide-1 Receptor Agonists",

author = "Pan, \{Heng Chih\} and Chen, \{Jui Yi\} and Chen, \{Hsing Yu\} and Yeh, \{Fang Yu\} and Sun, \{Chiao Yin\} and Huang, \{Thomas Tao Min\} and Wu, \{Vin Cent\}",

note = "{\textcopyright} 2024. The Author(s).",

year = "2024",

month = jul,

day = "13",

doi = "10.1038/s41467-024-50199-y",

language = "英语",

volume = "15",

pages = "5912",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease

AU - Pan, Heng Chih

AU - Chen, Jui Yi

AU - Chen, Hsing Yu

AU - Yeh, Fang Yu

AU - Sun, Chiao Yin

AU - Huang, Thomas Tao Min

AU - Wu, Vin Cent

PY - 2024/7/13

Y1 - 2024/7/13

N2 - Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.

AB - Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.

KW - Humans

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Glucagon-Like Peptide-1 Receptor/agonists

KW - Male

KW - Female

KW - Middle Aged

KW - Aged

KW - Acute Kidney Injury/mortality

KW - Hypoglycemic Agents/therapeutic use

KW - Cardio-Renal Syndrome/drug therapy

KW - Cardiovascular Diseases/mortality

KW - Treatment Outcome

KW - Glucagon-Like Peptide-1 Receptor Agonists

UR - https://www.scopus.com/pages/publications/85198325711

U2 - 10.1038/s41467-024-50199-y

DO - 10.1038/s41467-024-50199-y

M3 - 文章

C2 - 39003287

AN - SCOPUS:85198325711

SN - 2041-1723

VL - 15

SP - 5912

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 5912

ER -

GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this